Efficacy of Dalfampridine on Upper Extremity Function in Patients With MS
Status:
Unknown status
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
This study evaluates the effects of sustained-release oral dalfampridine in the treatment of
upper limb deficits in people with multiple sclerosis (MS). In this double-blind randomized
pilot study half of participants will dalfampridine, while the other half will receive a
placebo.